|
US5208036A
(en)
|
1985-01-07 |
1993-05-04 |
Syntex (U.S.A.) Inc. |
N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5283185A
(en)
|
1991-08-28 |
1994-02-01 |
University Of Tennessee Research Corporation |
Method for delivering nucleic acids into cells
|
|
US5412087A
(en)
|
1992-04-24 |
1995-05-02 |
Affymax Technologies N.V. |
Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
|
|
ATE219660T1
(de)
|
1994-09-30 |
2002-07-15 |
Inex Pharmaceuticals Corp |
Mittel zum einbringen polyanionischer materialien in zellen
|
|
US5753613A
(en)
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
|
US5695937A
(en)
|
1995-09-12 |
1997-12-09 |
The Johns Hopkins University School Of Medicine |
Method for serial analysis of gene expression
|
|
US7745651B2
(en)
|
2004-06-07 |
2010-06-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
|
CA2597724A1
(en)
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
EP3100718B1
(en)
|
2008-01-02 |
2019-11-27 |
Arbutus Biopharma Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
EP2279254B1
(en)
|
2008-04-15 |
2017-07-05 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
US9221902B2
(en)
|
2008-11-07 |
2015-12-29 |
Fabrus, Inc. |
Combinatorial antibody libraries and uses thereof
|
|
WO2010075303A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
|
|
US20110071208A1
(en)
|
2009-06-05 |
2011-03-24 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated dicer-substrate interfering rna
|
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
|
EA022786B1
(ru)
|
2009-07-31 |
2016-03-31 |
Этрис Гмбх |
Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
|
|
US9580714B2
(en)
|
2010-11-24 |
2017-02-28 |
The University Of Western Australia |
Peptides for the specific binding of RNA targets
|
|
ES2728782T3
(es)
|
2012-05-25 |
2019-10-28 |
Univ California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
|
CA2953341C
(en)
|
2014-06-25 |
2023-01-24 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
CA2969619A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
|
EP3247328B1
(en)
|
2015-01-21 |
2026-01-07 |
Genevant Sciences Gmbh |
Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
CA3012631A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
HUE067372T2
(hu)
|
2015-06-29 |
2024-10-28 |
Acuitas Therapeutics Inc |
Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
|
|
WO2017064546A1
(en)
*
|
2015-09-24 |
2017-04-20 |
Crispr Therapeutics Ag |
Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
|
|
CN116814590A
(zh)
|
2015-10-22 |
2023-09-29 |
布罗德研究所有限公司 |
Vi-b型crispr酶和系统
|
|
CN108368028B
(zh)
|
2015-10-28 |
2021-09-03 |
爱康泰生治疗公司 |
用于递送核酸的新型脂质和脂质纳米颗粒制剂
|
|
EP3374494A4
(en)
|
2015-11-11 |
2019-05-01 |
Coda Biotherapeutics, Inc. |
CRISPR COMPOSITIONS AND METHODS OF USE THEREOF FOR GENE THERAPY
|
|
EP3390624A4
(en)
|
2015-12-18 |
2019-07-10 |
The Regents of The University of California |
Modified site-directed modifying polypeptides and methods of use thereof
|
|
US9896696B2
(en)
|
2016-02-15 |
2018-02-20 |
Benson Hill Biosystems, Inc. |
Compositions and methods for modifying genomes
|
|
EP3468612A1
(en)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Hybrid carriers for nucleic acid cargo
|
|
WO2017212007A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Cationic carriers for nucleic acid delivery
|
|
CN109688820B
(zh)
|
2016-06-24 |
2023-01-10 |
科罗拉多州立大学董事会(法人团体) |
用于生成条形码化组合文库的方法
|
|
CN106057265B
(zh)
*
|
2016-07-08 |
2017-11-17 |
广东省稀有金属研究所 |
一种从萃取镧的废水中除放射性的方法
|
|
WO2018035250A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Methods for identifying class 2 crispr-cas systems
|
|
JP2019532644A
(ja)
|
2016-09-30 |
2019-11-14 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Rna誘導型核酸修飾酵素及びその使用方法
|
|
US9982267B2
(en)
|
2016-10-12 |
2018-05-29 |
Feldan Bio Inc. |
Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
|
|
EP3568470B1
(en)
|
2017-01-10 |
2022-07-06 |
Christiana Care Health Services, Inc. |
Methods for in vitro site-directed mutagenesis using gene editing technologies
|
|
US20190367924A1
(en)
|
2017-02-17 |
2019-12-05 |
Temple University - Of The Commonwealth System Of Higher Education |
Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5
|
|
MX2019011215A
(es)
|
2017-03-24 |
2020-02-12 |
Curevac Ag |
Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
|
|
US11773409B2
(en)
|
2017-04-21 |
2023-10-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
CRISPR/Cas 9-mediated integration of polynucleotides by sequential homologous recombination of AAV donor vectors
|
|
WO2019084148A1
(en)
|
2017-10-25 |
2019-05-02 |
Monsanto Technology Llc |
TARGETED RNA GUIDED ENDONUCLEASE ENDONUCLEASE ACTIVITY IN EUKARYOTES
|
|
US10253365B1
(en)
|
2017-11-22 |
2019-04-09 |
The Regents Of The University Of California |
Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs
|
|
EP3758714A4
(en)
|
2018-02-27 |
2021-12-01 |
The University of North Carolina at Chapel Hill |
METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN'S SYNDROME
|
|
US20200224160A1
(en)
|
2018-02-27 |
2020-07-16 |
Sorrento Therapeutics, Inc. |
Process for dna integration using rna-guided endonucleases
|
|
US12522811B2
(en)
|
2018-05-01 |
2026-01-13 |
The Children's Medical Center Corporation |
Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9
|
|
US20210139892A1
(en)
|
2018-07-05 |
2021-05-13 |
The Regents Of The University Of California |
Compositions and methods for delivery of rna to a cell
|
|
US20210284981A1
(en)
|
2018-07-24 |
2021-09-16 |
The Regents Of The University Of California |
Rna-guided nucleic acid modifying enzymes and methods of use thereof
|
|
EP3841205A4
(en)
|
2018-08-22 |
2022-08-17 |
The Regents of The University of California |
VARIANT TYPE V CRISPR/CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
SG11202113253SA
(en)
|
2019-06-07 |
2021-12-30 |
Scribe Therapeutics Inc |
Engineered casx systems
|
|
WO2020247883A2
(en)
|
2019-06-07 |
2020-12-10 |
Scribe Therapeutics Inc. |
Deep mutational evolution of biomolecules
|
|
WO2021007177A1
(en)
|
2019-07-08 |
2021-01-14 |
The Regents Of The University Of California |
Variant type v crispr/cas effector polypeptides and methods of use thereof
|
|
AU2020324386B2
(en)
|
2019-08-02 |
2026-04-23 |
Monsanto Technology Llc |
Methods and compositions to promote targeted genome modifications using HUH endonucleases
|
|
EP4028522A1
(en)
|
2019-09-09 |
2022-07-20 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of sod1
|
|
US12551560B2
(en)
|
2019-09-09 |
2026-02-17 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
|
IL292571A
(en)
|
2019-10-28 |
2022-06-01 |
Targetgene Biotechnologies Ltd |
Pam-reduced and pam-abolished cas derivatives compositions and uses thereof in genetic modulation
|
|
WO2021113772A1
(en)
|
2019-12-06 |
2021-06-10 |
Scribe Therapeutics Inc. |
Particle delivery systems
|
|
WO2021113763A1
(en)
|
2019-12-06 |
2021-06-10 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of rhodopsin
|
|
EP4069846A1
(en)
|
2019-12-07 |
2022-10-12 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of htt
|
|
JP2023510352A
(ja)
|
2020-01-10 |
2023-03-13 |
スクライブ・セラピューティクス・インコーポレイテッド |
Pcsk9の標的化のための組成物および方法
|
|
MX2022011460A
(es)
|
2020-03-18 |
2022-12-15 |
Scribe Therapeutics Inc |
Composiciones y métodos para el direccionamiento de c9orf72.
|
|
WO2022119957A1
(en)
|
2020-12-02 |
2022-06-09 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
|
EP4255502A4
(en)
|
2020-12-03 |
2025-07-16 |
Scribe Therapeutics Inc |
COMPOSITIONS AND METHODS FOR TARGETING BCL11A
|
|
AU2021392719B2
(en)
|
2020-12-03 |
2025-08-14 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
KR20230129395A
(ko)
|
2020-12-09 |
2023-09-08 |
스크라이브 테라퓨틱스 인크. |
유전자 편집을 위한 aav 벡터
|
|
CN117083385A
(zh)
|
2021-03-26 |
2023-11-17 |
特定生物制品公司 |
用双裂解内切核酸酶靶向致癌突变
|
|
WO2022261150A2
(en)
|
2021-06-09 |
2022-12-15 |
Scribe Therapeutics Inc. |
Particle delivery systems
|
|
IL311610A
(en)
|
2021-09-21 |
2024-05-01 |
Scribe Therapeutics Inc |
Engineered CASX suppressor systems
|
|
EP4405490A2
(en)
|
2021-09-23 |
2024-07-31 |
Scribe Therapeutics Inc. |
Self-inactivating vectors for gene editing
|
|
CA3257824A1
(en)
|
2022-06-02 |
2023-12-07 |
Scribe Therapeutics Inc. |
MODIFIED TYPE V, CLASS 2 CRISPR SYSTEMS
|
|
CN119998446A
(zh)
|
2022-06-07 |
2025-05-13 |
斯克里贝治疗公司 |
用于靶向pcsk9的组合物和方法
|
|
EP4536819A1
(en)
|
2022-06-07 |
2025-04-16 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
WO2023240157A2
(en)
|
2022-06-08 |
2023-12-14 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of dmd
|
|
WO2024206676A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of lpa
|